Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2019 Earnings Conference Call Transcript
Aug 07, 2019 • 04:30 pm ET
Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics Second Quarter 2019 Earnings Call. [Operator Instructions]
And now, I'd like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.
Thank you, Demetria. And thank you all for joining today's call. Earlier today, we released our financial results for the second quarter 2019. The press release is available on our website at www.sarepta.com and our 10-Q was filed with the SEC earlier this afternoon. Joining us on the call today are Doug Ingram, Sandy Mahatme, Bo Cumbo, Dr. Gilmore O'Neill, and Dr. Louise Rodino-Klapac. Ater our formal remarks, we'll open up the call for Q&A.
I'd like to note that during this call, we'll be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, any of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements and any such risk can materially and adversely affect the business, results of operations and trading prices for Sarepta's common stock.
For a detailed description of applicable risks and uncertainties, we encourage you to review the Company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as well as the Company's other SEC filings. The Company does not undertake any obligation to publicly update its forward-looking statements, including any financial projections provided today based on subsequent events or circumstances.
And with that, let me turn the call over to our CEO, Doug Ingram, who will provide an overview of our recent progress. Doug?
Douglas S. Ingram
Thank you, Ian. Good afternoon, and thank you all for joining us for Sarepta Therapeutics second quarter 2019 results and corporate update conference call. As we pass through mid-year, let's linger for a moment on our progress today. As we entered 2019, we set an ambitious path requiring significant execution and with much still to prove for the RNA platform, should we continue to drive the EXONDYS performance. Should we consistently create new PMO constructs for other populations of Duchenne, and have we truly enforced with the FDA efficient pathway for approval of efficacious new RNA therapies, one that could bring new treatments to the community rapidly and without unnecessary controversy and contention.
For the gene therapy platform with the stellar initial results that we've seen with our micro-dystrophin gene therapy truly readthrough any of the other 10 plus gene therapy programs that we possess. For micro-dystrophin gene therapy itself, can we quickly complete the dosing of the 24 patients in our placebo-controlled trial for micro-dystrophin, what would be the competitive landscape for micro-dystrophin would we remain ahead of others of sort of loyalty and qualitatively. And when we develop the resources, the talent, the energy necessary to build out on commercial manufacturing process for gene therapy. Over the course of 2019, the answers to these questions have been positive.